Bicycle Therapeutics (BCYC) Expected to Announce Quarterly Earnings on Thursday

Bicycle Therapeutics (NASDAQ:BCYC) will likely be announcing its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of ($1.05) per share for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, October 30, 2025 at 7:00 AM ET.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%.The company had revenue of $2.90 million during the quarter, compared to the consensus estimate of $9.43 million. On average, analysts expect Bicycle Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Bicycle Therapeutics Stock Down 4.9%

BCYC opened at $7.88 on Thursday. The stock has a market capitalization of $546.16 million, a price-to-earnings ratio of -2.25 and a beta of 1.47. The firm has a 50 day moving average price of $7.53 and a 200-day moving average price of $7.79. Bicycle Therapeutics has a twelve month low of $6.10 and a twelve month high of $26.57.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Royal Bank Of Canada set a $27.00 target price on shares of Bicycle Therapeutics and gave the company an “outperform” rating in a research note on Monday, August 11th. JMP Securities cut their price objective on Bicycle Therapeutics from $22.00 to $10.00 and set a “market outperform” rating for the company in a report on Tuesday, August 12th. Morgan Stanley lowered their target price on Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 12th. Oppenheimer reissued an “outperform” rating and issued a $44.00 target price (down from $48.00) on shares of Bicycle Therapeutics in a research report on Monday, August 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Bicycle Therapeutics in a research note on Tuesday, October 14th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bicycle Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.22.

Insider Transactions at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of the business’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $8.41, for a total transaction of $27,172.71. Following the completion of the sale, the chief executive officer owned 475,310 shares of the company’s stock, valued at approximately $3,997,357.10. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 8,527 shares of company stock worth $71,738 over the last three months. Insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Bicycle Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State of Tennessee Department of Treasury bought a new position in shares of Bicycle Therapeutics in the second quarter worth approximately $100,000. Soleus Capital Management L.P. bought a new stake in shares of Bicycle Therapeutics during the 2nd quarter valued at $695,000. Monimus Capital Management LP purchased a new position in shares of Bicycle Therapeutics during the 2nd quarter valued at $592,000. Rangeley Capital LLC bought a new position in Bicycle Therapeutics in the 2nd quarter worth $521,000. Finally, Moore Capital Management LP increased its stake in Bicycle Therapeutics by 50.0% in the 2nd quarter. Moore Capital Management LP now owns 75,000 shares of the company’s stock worth $521,000 after buying an additional 25,000 shares in the last quarter. 86.15% of the stock is owned by hedge funds and other institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.